Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative disorders that affects the basal ganglia and the motor system (parkinsonism), autonomic nervous system (dysautonomia ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

No specific neuroprotective treatment is available so far, leaving a survival time of usually less than 10 years after the ...

To learn more, the researchers enrolled 428 people, aged between 40-99, with a clinical diagnosis of Parkinson’s, dementia with Lewy bodies, multiple system atrophy and pure autonomic failure.

The present study emphasizes the importance of myelin degeneration in the pathogenesis of multiple system atrophy.

placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy (MSA). The topline data showed that ATH434 produced clinically and statistically significant ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function ...

Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of ...

While Parkinson's disease accounts for 80% of all Parkinsonism cases, other conditions — multiple system atrophy or corticobasal degeneration — can also cause the symptoms. "The Eagles will be ...